Olivier Mir

15.6k total citations · 1 hit paper
287 papers, 6.4k citations indexed

About

Olivier Mir is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Olivier Mir has authored 287 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Pulmonary and Respiratory Medicine, 140 papers in Oncology and 42 papers in Surgery. Recurrent topics in Olivier Mir's work include Sarcoma Diagnosis and Treatment (99 papers), Vascular Tumors and Angiosarcomas (35 papers) and Gastrointestinal Tumor Research and Treatment (34 papers). Olivier Mir is often cited by papers focused on Sarcoma Diagnosis and Treatment (99 papers), Vascular Tumors and Angiosarcomas (35 papers) and Gastrointestinal Tumor Research and Treatment (34 papers). Olivier Mir collaborates with scholars based in France, United States and United Kingdom. Olivier Mir's co-authors include François Goldwasser, Stanislas Ropert, Romain Coriat, Pascaline Boudou‐Rouquette, Jean‐Yves Blay, Axel Le Cesne, Paul Berveiller, Benoı̂t Blanchet, Antoîne Italiano and Stanislas Chaussade and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Olivier Mir

276 papers receiving 6.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

2018 229 citations Florence Duffaud, Olivier Mir et al. The Lancet Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Olivier Mir	2.9k	2.8k	1.2k	817	760	287	6.4k
Karen H. Antman	3.5k 1.2×	3.3k 1.2×	1.2k 1.0×	633 0.8×	739 1.0×	146	8.4k
Martin J. Heslin	3.1k 1.1×	2.1k 0.8×	1.0k 0.9×	350 0.4×	2.0k 2.6×	142	6.2k
Steven G. DuBois	2.0k 0.7×	2.7k 1.0×	2.4k 2.1×	614 0.8×	856 1.1×	281	7.4k
Florence Duffaud	1.8k 0.6×	3.4k 1.2×	869 0.7×	1.1k 1.3×	1.0k 1.3×	231	5.6k
Modesto Carli	1.7k 0.6×	4.0k 1.4×	1.9k 1.6×	1.2k 1.4×	1.4k 1.8×	171	7.2k
Sameer Bakhshi	1.4k 0.5×	1.4k 0.5×	911 0.8×	550 0.7×	679 0.9×	509	5.2k
Mitchell C. Posner	2.9k 1.0×	2.5k 0.9×	1.0k 0.9×	284 0.3×	2.3k 3.1×	175	6.4k
Esther Bastiaannet	4.5k 1.6×	1.6k 0.6×	847 0.7×	246 0.3×	1.6k 2.1×	263	6.9k
Nicholas G. Zaorsky	2.5k 0.9×	3.1k 1.1×	827 0.7×	183 0.2×	876 1.2×	229	6.7k
Bruno Vincenzi	6.2k 2.2×	3.2k 1.2×	2.6k 2.2×	575 0.7×	1.6k 2.2×	428	11.0k

Countries citing papers authored by Olivier Mir

Since Specialization

Citations

This map shows the geographic impact of Olivier Mir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Mir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Mir more than expected).

Fields of papers citing papers by Olivier Mir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Mir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Mir. The network helps show where Olivier Mir may publish in the future.

Co-authorship network of co-authors of Olivier Mir

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Mir. A scholar is included among the top collaborators of Olivier Mir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Mir. Olivier Mir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blatzer, Michael, Anita Kneppers, David Briand, et al.. (2024). Serotonin reuptake inhibitors improve muscle stem cell function and muscle regeneration in male mice. Nature Communications. 15(1). 1 indexed citations

Bertucci, François, Alexandre de Nonneville, Pascal Finetti, et al.. (2022). Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature. Journal for ImmunoTherapy of Cancer. 10(1). e003687–e003687. 17 indexed citations

Kyriazoglou, Anastasios, Olivier Mir, Bernd Kasper, et al.. (2022). Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 ‘CaboGIST’. Acta Oncologica. 61(6). 663–668. 1 indexed citations

Jones, Robin L., César Serrano, Margaret von Mehren, et al.. (2021). Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. European Journal of Cancer. 145. 132–142. 85 indexed citations

Honoré, Charles, Arthur Géraud, Nicolas Epaillard, et al.. (2021). RCP Pacifique : bilan après un an et 323 cancers rares et/ou complexes discutés. Bulletin du Cancer. 108(12). 1077–1084.

Honoré, Charles, Olivier Mir, Arthur Géraud, et al.. (2021). Intercontinental Multidisciplinary Oncology Videoconferencing for Rare and Complex Cancer: An Alternative to Systematic Transfer. JCO Oncology Practice. 17(9). e1311–e1317. 3 indexed citations

Nassif, Elise F., Édouard Auclin, Rastilav Bahleda, et al.. (2021). TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials. Cancers. 13(13). 3362–3362. 7 indexed citations

Lesluyes, Tom, Christine Ménétrier‐Caux, Mehdi Brahmi, et al.. (2020). Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. OncoImmunology. 9(1). 1792036–1792036. 30 indexed citations

Boilève, Alice, Armelle Dufresne, Ali N. Chamseddine, et al.. (2020). Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. ESMO Open. 5(6). e001082–e001082. 2 indexed citations

10.

Brodowicz, Thomas, Bernadette Liegl‐Atzwanger, Nicolas Penel, et al.. (2020). Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. Cancers. 12(12). 3746–3746. 8 indexed citations

11.

Mir, Olivier, Sarah Watson, & Jean‐Yves Blay. (2020). Letter: Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. Neurosurgery. 86(5). E480–E482. 2 indexed citations

12.

Toulmonde, Maud, Jean‐Yves Blay, Olivier Bouché, et al.. (2019). Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. Clinical Cancer Research. 25(15). 4611–4615. 14 indexed citations

13.

Sanfilippo, Roberta, Robin L. Jones, Jean‐Yves Blay, et al.. (2019). Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). Clinical Cancer Research. 25(17). 5295–5300. 75 indexed citations

14.

Mir, Olivier, Nathan Touati, Michela Lia, et al.. (2019). Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. Clinical Cancer Research. 25(5). 1479–1485. 64 indexed citations

15.

Verspoor, F.G.M., M.J.L. Mastboom, Gerjon Hannink, et al.. (2019). Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. Scientific Reports. 9(1). 14551–14551. 46 indexed citations

16.

Brodowicz, Thomas, Olivier Mir, Jennifer Wallet, et al.. (2018). Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. European Journal of Cancer. 99. 28–36. 15 indexed citations

17.

Italiano, Antoîne, Valérie Laurence, Nicolas Penel, et al.. (2017). A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. Scientific Reports. 7(1). 17917–17917. 8 indexed citations

18.

Cesne, Axel Le, Jean‐Yves Blay, Julien Dômont, et al.. (2015). Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. The Lancet Oncology. 16(3). 312–319. 63 indexed citations

19.

Coriat, Romain, Jérôme Alexandre, Carole Nicco, et al.. (2013). Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir. Journal of Clinical Investigation. 124(1). 262–272. 64 indexed citations

20.

Coriat, Romain, Carole Nicco, Christiane Chéreau, et al.. (2012). Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo. Molecular Cancer Therapeutics. 11(10). 2284–2293. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact